FDA halts Amgen study after teen patient death
WASHINGTON (AP) — Federal health regulators have halted Amgen’s studies of its drug Sensipar after the death of a 14-year-old patient in a company trial.
Good Health is Your Greatest Wealth……Virgil
WASHINGTON (AP) — Federal health regulators have halted Amgen’s studies of its drug Sensipar after the death of a 14-year-old patient in a company trial.